The latest breast cancer research could lead to more personalised care for patients and help further understanding of the causes of the disease, scientists said.

A study involving people from around the world has been hailed as giving a more complete picture of the changes in DNA in breast cancer, providing potential opportunities for new treatments.

A study of 560 breast cancer genomes, or complete genetic codes, turned up five new genes associated with the disease.

The results, published in Nature and Nature Communications, provide evidence that breast cancer genomes are “highly individual”, researchers from the Wellcome Trust Sanger Institute said.

It is a step closer to personalised healthcare for cancer

The team looked at genomes in patients, four of whom were men, and focused on mutations that encourage the disease to grow and the patterns – known as mutational signatures – in each tumour.

They found that women with genes that leave them at a higher risk of developing breast and ovarian cancer, have entire genome profiles that are very different to each other and distinctive from other breast cancers.

Serena Nik-Zainal, who led the team of researchers, said: “In the future, we’d like to be able to profile individual cancer genomes so that we can identify the treatment most likely to be successful for a woman or man diagnosed with breast cancer. It is a step closer to personalised healthcare for cancer.”

Moreover, Ewan Birney, from the European Bioinformatics Institute, analysed the sequence of genetic information in the sample genomes.

He said: “This study simultaneously gave us the first large- scale view of the rest of the genome, uncovering some new reasons as to why breast cancer arises, and also gave us an unexpected way to characterise the types of mutations that happen in certain breast cancers.”

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.